Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: A multicenter trial

Circulation

Volumn 94, Issue 10, 1996, Pages 2389-2395

  Koneti Rao, A ^a   Sun, Ling ^b   Chesebro, James H ^b   Fuster, Valentin ^b   Harrington, Robert A ^b   Schwartz, Darryl ^b   Gallo, Paul ^b   Matos, Deborah ^b   Topol, Eric J ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

angina; anticoagulants; coagulation; heparin; hirudin

Indexed keywords

DESULFATOHIRUDIN; FIBRINOPEPTIDE A; HEPARIN; LEPIRUDIN; PROTHROMBIN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; UNSTABLE ANGINA PECTORIS;

EID: 10544245025     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.94.10.2389     Document Type: Article

References (38)

1. Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med. 1986;315:1023-1024.
2. Deutsch E, Rao AK, Colman RW. Selective thrombin inhibitors: the next generation of anticoagulants. J Am Coll Cardiol 1993;22:1089-1092.
3. Eisenberg PR, Sherman LA, Schectmann K, Peres J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation. 1985;71:912-918.
4. Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation. 1992;85:928-934.
5. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
6. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994;74:1-23.
7. Becker RC, Cannon CP. Hirudin: its biology and clinical use. J Thromb Thrombolysis. 1994;1:7-16.
8. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 1986;25:4622-4628.
9. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost. 1990;64:464-468.
10. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973;248:6490-6505.
11. Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem. 1982;48:161-182.
12. Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J. 1987;243:579-588.
13. Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Blajchman MA. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J. 1989;257:143-150.
14. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost. 1988;60:457-462.
15. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
16. Heras M, Chesebro JH, Penny WS, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on development of acute plateletthrombus deposition during angioplasty in pigs. Circulation. 1989;79:657-665.
17. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a por cine model: effects of hirudins, heparin, and calcium chelation. Blood. 1991;78:423-434.
18. Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost. 1990;63:204-207.
19. Agnelli G, Renga C, Weitz J, Nenci G, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood. 1992;80:960-965.
20. Verstraete M, Hurmoharned M, Kienast J, Siebeck M, Silling-Engelhardt G, Buller H, Hoet B, Bichler J, Close P. Biological effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol. 1993;22:1080-1092.
21. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Caspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. Circulation. 1993;88:2015-2022.
22. Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster VE, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during inhibition with hirudin. Circulation. 1994;90:2671-2678.
23. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Muller HS, Becker RC, Klieman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared to heparin in conjunction with tissue plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23:993-1003.
24. Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI 6) Trial. Am J Cardiol. 1995;75:7-13.
25. Zeymer U, Jessel A, Neuhaus K-L. Hirudin as conjunctive therapy in patients with thrombolysis for acute myocardial infarction produced stable prolongation of ACT and APTT. Circulation. 1993;88(suppl I):I-201. Abstract.
26. Zeymer U, von Essen R, Tebbe U, Michaels HR, Jessel A, Vogt A, Roth M, Appel KF, Neuhaus K-L. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study: HIT-I (Hirudin for Improvement of Thrombolysis). Eur Heart J. 1995;16(suppl D):22-27.
27. van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rijnierse JJMM. Buller HR, Serruys PW. Safety and efficacy of recombinant hirudin (CGP 39,393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993;88:2058-2066.
28. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA. Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1566.
29. Amiral J, Walenga JM, Fareed J. Development and performance characteristics of enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemost. 1984;10:128-242.
30. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York, NY: John Wiley & Sons: 1987:54-55.
31. Nossel HL, Yudelman I, Canfield RE, Butler VP Jr, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974;54:43-53.
32. Bauer KA, Goodman TM, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest. 1985;76:826-836.
33. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem. 1978;253:6908-6916.
34. Marciniak E. Factor Xa inactivation by antithrombin III: evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol. 1973;24:391-400.
35. Walker FJ, Esmon CT. The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. Biochem Biophys Res Commun. 1979;90:642-647,
36. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrornbin complex. J Clin Invest. 1983;71:1383-1389.
37. Gallistl S, Muntean W. Thrombin-hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost. 1994;72:387-392.
38. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.